NCT04573348 is a clinical trial of Savicell's ImmunoBiopsy™ in Covid19, sponsored by Savicell Diagnostics Ltd.

Who is sponsoring NCT04573348?

NCT04573348 is sponsored by Savicell Diagnostics Ltd.

What drugs are being tested in NCT04573348?

Interventions in NCT04573348: Savicell's ImmunoBiopsy™.

What condition does NCT04573348 study?

NCT04573348 studies Covid19, Corona Virus Infection.

Is NCT04573348 still recruiting?

NCT04573348 is currently status unknown. Last updated 2 November 2020.

Last reviewed 2020-11-02 · How we verify

NCT04573348

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

T Cells Response to SARS COV 2 Peptides

Status unknown Last updated 2 November 2020

What this trial tests

trial testing Savicell's ImmunoBiopsy™ in Covid19 in 400 participants. Status unknown.

Timeline

14 October 2020

Primary endpoint
10 May 2021

10 October 2021

Quick facts

Lead sponsor	Savicell Diagnostics Ltd
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	400
Start date	14 October 2020
Primary completion	10 May 2021
Estimated completion	10 October 2021
Sites	1 location across Israel

Drugs / interventions tested

Savicell's ImmunoBiopsy™

Conditions studied

Covid19 — all drugs for Covid19 →
Corona Virus Infection — all drugs for Corona Virus Infection →

Sponsor

Savicell Diagnostics Ltd

Who can join

18 and older, any sex, with Covid19 or Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral Blood Mononuclear Cells (PBMC) in response to various reagents at different concentrations. The purpose of this study is to evaluate the T cells reactivity to SARS COV 2 immunogenic selected peptides by Metabolic Activity Method in convalesce and healthy individuals and to compare it with Antibody response (ELISA) and clinical information

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04573348 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Savicell Diagnostics Ltd
Last refreshed: 2 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04573348.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing